Winald R. Gerritsen
Radboud University Nijmegen
206 Papers
1.3K Citations
Winald R. Gerritsen is an academic researcher from Radboud University Nijmegen. The author has contributed to research in topics: Medicine & Prostate cancer. The author has an hindex of 33, co-authored 179 publications. Previous affiliations of Winald R. Gerritsen include Radboud University Nijmegen Medical Centre & VU University Medical Center.
Chat about Author
Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt,Ronald de Wit,David J. Vaughn,Yves Fradet,Jae-Lyun Lee,Lawrence Fong,Nicholas J. Vogelzang,Miguel Angel Climent,Daniel P. Petrylak,Toni K. Choueiri,Andrea Necchi,Winald R. Gerritsen,Howard Gurney,David I. Quinn,Stéphane Culine,Cora N. Sternberg,Yabing Mai,Christian Heinrich Poehlein,Rodolfo F. Perini,Dean F. Bajorin +19 more
TL;DR: Pembrolizumab was associated with significantly longer overall survival and with a lower rate of treatment‐related adverse events than chemotherapy as second‐line therapy for platinum‐refractory advanced urothelial carcinoma.
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Eugene D. Kwon,Charles G. Drake,Howard I. Scher,Karim Fizazi,Alberto Bossi,Alfons J.M. van den Eertwegh,Michael Krainer,Nadine Houede,Ricardo Santos,Hakim Mahammedi,Siobhan Ng,Michele Maio,Fabio Franke,Santhanam Sundar,Neeraj Agarwal,Andries M. Bergman,Tudor Ciuleanu,Ernesto Korbenfeld,Lisa Sengeløv,Steinbjørn Hansen,Christopher J. Logothetis,Tomasz M. Beer,M. Brent McHenry,Paul Gagnier,David R. Liu,Winald R. Gerritsen +25 more
TL;DR: There was no significant difference between the ipilimumab group and the placebo group in terms of overall survival in the primary analysis, but there were signs of activity with the drug that warrant further investigation.
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
Tomasz M. Beer,Eugene D. Kwon,Charles G. Drake,Karim Fizazi,Christopher J. Logothetis,Gwenaelle Gravis,Vinod Ganju,Jonathan Polikoff,Fred Saad,Piotr Humanski,Josep M. Piulats,Pablo González Mella,Siobhan Ng,Dirk Jaeger,Francis Parnis,Fabio Franke,J. Puente,Roman Carvajal,Lisa Sengeløv,M. Brent McHenry,Arvind Varma,Alfonsus J. M. van den Eertwegh,Winald R. Gerritsen +22 more
TL;DR: Ipilimumab did not improve OS in patients with metastatic castration-resistant prostate cancer and the observed increases in progression-free survival and prostate-specific antigen response rates suggest antitumor activity in a patient subset.
698
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Thomas Powles,Thomas Powles,Tibor Csőszi,Mustafa Ozguroglu,Nobuaki Matsubara,Lajos Géczi,Susanna Y-S Cheng,Yves Fradet,Stéphane Oudard,Christof Vulsteke,Rafael Morales Barrera,Aude Flechon,Seyda Gunduz,Yohann Loriot,Alejo Rodriguez-Vida,Ronac Mamtani,Evan Y. Yu,Evan Y. Yu,Kijoeng Nam,Kentaro Imai,Blanca Homet Moreno,Ajjai Alva,Diana Vera Cascallar,Mirta Varela,Mauricio Fernandez Lazzaro,Diego Lucas Kaen,Gabriela Gatica,David Hugo Flores,Agustin Falco,Matias Molina,Filip Van Aelst,Brieuc Sautois,Jean-Pascal Machiels,Denis Schallier,Leandro Brust,Liane Rapatoni,Sergio J Azevedo,Gisele Marinho,Joao Paulo Holanda Soares,Carlos Dzik,Jamile Almeida Silva,Andre P. Fay,Joel Gingerich,Cristiano Ferrario,Kylea Potvin,Marie Vanhuyse,Mahmoud Abdelsalam,Susanna Cheng,Christian Caglevic,Felipe Reyes,Jose Luis Leal,Francisco Francisco,Carolina Ibanez,Florence Joly,Brigitte Laguerre,Sylvain Ladoire,Delphine Topart,Olivier Huillard,Marine Gross-Goupil,Stéphane Culine,Gwenaelle Gravis,Peter Reichardt,Margitta Retz,Jan Herden,David G. Pfister,Carsten Ohlman,Michael Stoeckle,Manfred P. Wirth,Anja Lorch,Guenter Niegisch,Peter J. Goebell,Martin Boegemann,Axel S. Merseburger,Georgios Gakis,Jens Bedke,Andreas Neisius,Christian Thomas,Thomas Hoefner,Andras Telekes,Judit Erzsebet Kosa,János Révész,György Bodoky,Tibor Csoszi,Andras Csejtei,Agnes Ruzsa,Zsuzsanna Kolonics,Jozsef Erfan,Ray McDermott,Richard Bambury,Avishay Sella,Stephen Jay Frank,Daniel Kejzman,Olesya Goldman,Eli Rosenbaum,Avivit Peer,Raanan Berger,Keren Rouvinov,David Sarid,Satoshi Fukasawa,Gaku Arai,Akito Yamaguchi,Akira Yokomizo,Tatsuya Takayama,Hidefumi Kinoshita,Eiji Kikuchi,Ryuichi Mizuno,Yasuhisa Fujii,Naoto Sassa,Yoshihisa Matsukawa,Kiyohide Fujimoto,Toshiki Tanikawa,Yoshihiko Tomita,Kazuo Nishimura,Masao Tsujihata,Masafumi Oyama,Naoya Masumori,Hiroomi Kanayama,Toshimi Takano,Yuji Miura,Jun Miyazaki,Akira Joraku,Tomokazu Kimura,Yoshiaki Yamamoto,Kazuki Kobayashi,Ronald de Wit,Maureen J.B. Aarts,Winald R. Gerritsen,Maartje Los,Laurens V. Beerepoot,Adel Izmailov,Sergey Igorevich Gorelov,Boris Alekseev,Andrey Semenov,Vladimir Anatolyevich Kostorov,Sergey M Alekseev,Alexander Zyryanov,Vasiliy Nikolaevich Oschepkov,Vladimir Aleksandrovich Shidin,Vladimir Ivanovich Vladimirov,Rustem Gafanov,Petr Alexandrovich Karlov,David Brian Anderson,Lucinda Shepherd,Graham Lawrence Cohen,Bernardo Louis Rapoport,Paul Ruff,Nari Lee,Woo Kyun Bae,Hyo Jin Lee,Urbano Anido Herranz,Enrique Grande,Teresa Alonso Gordoa,Josep Guma Padro,Daniel Castellano Gauna,Jose Angel Arranz,Jose Munoz Langa,Regina Gironés Sarrió,Alvaro Montesa Pino,Maria Jose Juan Fita,Yu-Li Su,Yung-Chang Lin,Wen-Pin Su,Ying-Chun Shen,Yen-Hwa Chang,Yi-Hsiu Huang,Virote Sriuranpong,Phichai Chansriwong,Vichien Srimuninnimit,Pongwut Danchaivijitr,Huseyin Abali,Sinan Yavuz,Ozgur Ozyilkan,Mehmet Ali Nahit Sendur,Meltem Ekenel,Cagatay Arslan,Mustafa Ozdogan,Alison Birtle,Robert Huddart,Maria De Santis,Anjali Zarkar,Linda Evans,Syed A. Hussain,Christopher DiSimone,Antonio F Muina,Peter Schlegel,Haresh S Jhangiani,Michael R. Harrison,Dennis E Slater,David Wright,Ivor J. Percent,Jianqing Lin,Clara Hwang,Sumati Gupta,Madhuri Bajaj,Robert Galamaga,John Eklund,James Wallace,Mikhail Shtivelband,Jason Jung-Gon Suh,Nafisa Burhani,Matthew Eadens,Krishna Gunturu,Earle Burgess,John Wong,Arvind Chaudhry,Peter J. Van Veldhuizen,Stephanie Graff,Christian A Thomas,Ian D. Schnadig,Benedito A. Carneiro,Maha Hussain,Alicia K. Morgans,John T Fitzharris,Ira A Oliff,Jacqueline Vuky,Ralph Hauke,Ari David Baron,Monika Joshi,Britt H Bolemon,Peter Jiang,Anthony Mega,Maurice Markus,Nicklas Pfanzelter,William E. Lawler,Patrick Wayne Cobb,Jay Courtright,Sharad Jain,Gurjyot Doshi,Vijay K Gunuganti,Oliver Sartor,Scott W Cole,Hani M. Babiker,Edward Uchio,Alexandra Drakaki,Heather D Mannuel,Elizabeth A. Guancial,Chunkit Fung,Anthony Charles,Robert J Amato,Yull Arriaga,Isaac Bowman,Steven Ades,Robert Dreicer,Evan Yu,David I. Quinn,Mark D. Fleming +245 more
TL;DR: In this paper, the authors assessed outcomes with first-line pembrolizumab alone or combined with chemotherapy versus chemotherapy for patients with previously untreated advanced urothelial carcinoma.
541
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
Yves Fradet,Joaquim Bellmunt,David J. Vaughn,J.-L. Lee,Lawrence Fong,N. J. Vogelzang,Miguel Angel Climent,Daniel P. Petrylak,Toni K. Choueiri,Andrea Necchi,Winald R. Gerritsen,Howard Gurney,David I. Quinn,Stéphane Culine,Cora N. Sternberg,Kijoeng Nam,Tara L. Frenkl,Rodolfo F. Perini,R. de Wit,Dean F. Bajorin +19 more
TL;DR: Long-term results (>2 years’ follow-up) were consistent with those of previously reported analyses, demonstrating continued clinical benefit of pembrolizumab over chemotherapy for efficacy and safety for treatment of locally advanced/metastatic, platinum-refractory UC.
431